Adalimumab Biosimilars Market to Hit USD 6044.9 Million by 2033, With 23.4% CAGR
The Adalimumab Biosimilars Market size is anticipated to expand significantly, with forecasts suggesting an escalation from USD 738.3 million in 2023 to an estimated USD 6044.9 million by 2033. This projected growth is indicative of a compound annual growth rate (CAGR) of 23.4% over the decade spanning from 2024 to 2033. Adalimumab, marketed as Humira, stands as the highest-grossing drug globally since its 2002 FDA approval. This fully humanized monoclonal antibody has revolutionized treatment in various inflammatory conditions. Its patent expiration in 2016 paved the way for competitors like Novartis, Mylan, Biogen, and Amgen to introduce biosimilars. Biosimilars, akin to…
- Date: March 6, 2024
- Author: Robert Shaw
- Category: PharmiWeb